Please assess the completion status of the following clinical trial:

Trial Title: Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Proof of primary varicella infection (chicken pox) either by appropriate history (as defined by ACIP) or otherwise confirmed with a positive VZV IgG antibody level~2. Patient has a history of ulcerative colitis (UC) diagnosed by standard clinical, radiographic, endoscopic, and histopathologic criteria~3. Patient is receiving one of the following treatments for their UC:~Group A: Tofacitinib monotherapy, Group B: Anti-TNF monotherapy (adalimumab, golimumab, certolizumab pegol, infliximab), Group C: Anti-TNF combination therapy with a thiopurine (6 mercaptopurine, azathioprine), Group D: 5-aminosalicylates or other non-immunomodulatory therapy.~Exclusion Criteria:~1. Previous receipt of any HZ vaccine~2. Allergy to zoster vaccine or a component of the vaccine~3. Other underlying chronic medical conditions that could affect immunogenicity to vaccines (rheumatoid arthritis, psoriasis etc.)~4. History of herpes zoster infection or post herpetic neuralgia~5. Patient cannot or will not provide written informed consent~6. Patient is on a non-licensed or experimental immunomodulator~7. Patient is on methotrexate~8. Patient has received immunoglobulin therapy or blood products with the past month~9. Currently pregnant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- UC patients on tofacitinib monotherapy (Type: EXPERIMENTAL): Ulcerative Colitis patients on Tofacitinib monotherapy, all patients will be treated with the standard Tofacitinib and will receive Shingrix vaccine.
- UC patients on anti-TNF monotherapy (Type: ACTIVE_COMPARATOR): Ulcerative Colitis patients on anti-TNF monotherapy, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab)and will receive Shingrix vaccine.
- UC patients on anti-TNF and a thiopurine (Type: ACTIVE_COMPARATOR): Ulcerative Colitis patients on anti-TNF and a thiopurine, all patients will be treated with the standard anti-TNF monotherapy (adalimumab, golimumab, certolizumab, infliximab) and thiopurine (6-mercaptopurine, azathioprine) and will receive Shingrix vaccine.
- UC pts. on aminosalicylates or off immunomodulatory therapy (Type: ACTIVE_COMPARATOR): Ulcerative Colitis patients on non-immunosuppressive therapy or 5-aminosalicylates, all patients will be treated with the standard non-immunosuppressive therapy or 5-aminosalicylates and will receive Shingrix vaccine.

Based on this trial design, predict the completion outcome and termination type (if applicable).